Top Companies in CAR T-cell Therapy (2026)
Last updated October 2026 · Originally published November 2022 At first, the trend was subtle. But, the tide has swelled and created a craze for promising CAR-T product candidates. Driven by approvals of the CAR-T products Kymriah and Yescarta, there has been a rush to chase the next CAR-T success. CAR T-cell therapy (Chimeric Antigen Receptor T-Cell) is a type of immunotherapy where doctors collect immune cells, modify them in a laboratory, and provide them the power to easily recognize and kill cancer cells. When infused into a patient, the cells get multiplied and stay in the body as “living drugs.” The global CAR t-cell therapy market size was valued at USD 5.8 billion in 2025 and is projected to grow from USD 6.9 billion in 2026 to USD 22.3 billion by 2033, at a CAGR of 18.1% from 2026 to 2033. The market in North America dominated with a revenue share of 61.1% in 2025. Market growth is driven by rising cancer prevalence, adoption of personalized c...